Dental Care Clinics in Harlan, IA Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 White Pine Dental Group Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2105 Pine St, Harlan, IA 51537 Phone: 712-755-5342 Fax: 712-755-5666 |
Morningview Dental, Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1116 Morningview Dr., Harlan, IA 51537 Phone: 712-755-5342 Fax: 712-755-5666 |
Legendary Dental Pllc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1809 21st St, Harlan, IA 51537 Phone: 712-340-0333 |
Cornerstone Dental Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1818 Chatburn Plz, Harlan, IA 51537 Phone: 319-471-4031 |
Markham Family Dental Associates, Inc. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2105 Pine St, Harlan, IA 51537 Phone: 712-755-5342 Fax: 712-755-5666 |
News Archive
Spanish researchers produce proper human skin using new 3D printing technology
This research has recently been published in the electronic version of the scientific journal Biofabrication.
Three toxins in food identified as triggers to gluten intolerance: study
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
UCLH selects Nexthink's V5 modular platform to improve IT infrastructure
Nexthink, the unique provider of End-user IT Analytics, has today announced that its V5 modular platform has been selected by University College London Hospitals NHS Foundation Trust to provide real-time visibility and analytics across its technical estate and network infrastructure.
Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD
Oxford BioMedica plc, a leading gene therapy company, today announces that the first dose level of RetinoStat is safe and well-tolerated at one month following treatment.
› Verified 2 days ago